BridgeBio Pharma (BBIO) Cash & Current Investments (2017 - 2026)

BridgeBio Pharma has disclosed Cash & Current Investments across 10 years of filings, most recently posting $940.2 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $940.2 million, up 73.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $940.2 million (up 73.92% YoY), and the FY2025 annual result was $587.5 million, down 13.75% from the prior year.
• Cash & Current Investments came in at $940.2 million for Q1 2026 at BridgeBio Pharma, up from $587.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $940.2 million in Q1 2026 to a low of $266.3 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $540.6 million (2025), against an average of $533.6 million.
• Across the five-year window, Cash & Current Investments plunged 53.18% in 2023 and jumped 73.92% in 2026, its largest moves.
• BridgeBio Pharma's Cash & Current Investments stood at $414.6 million in 2022, then increased by 4.89% to $434.9 million in 2023, then jumped by 56.62% to $681.1 million in 2024, then fell by 13.75% to $587.5 million in 2025, then jumped by 60.04% to $940.2 million in 2026.
• The last three Cash & Current Investments figures came in at $940.2 million (Q1 2026), $587.5 million (Q4 2025), and $286.3 million (Q3 2025), per Business Quant data.